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PolyaminePrion proteins are known as the main agents of transmissible spongiform encephalopathies affecting humans
as well as animals. A recombinant ovine prion protein was found to be in vitro able to act as an effective sub-
strate for a microbial isoform of transglutaminase, an enzyme catalyzing the formation of isopeptide bonds
inside the proteins. We proved that transglutaminase modiﬁes the structure of the prion protein by leading
to the formation of three intra-molecular crosslinks and that the crosslinked protein form is more competent
in amyloid formation compared to the unmodiﬁed one. In addition, the crosslinked prion protein was shown
also to be more resistant to proteinase K digestion. Our ﬁndings suggest a possible use of transglutaminase in
stabilizing the prion protein three-dimensional structure in order to investigate the molecular basis of the
conversion of the protein into its pathological form.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Prion dependent transmissible spongiform encephalopathies (TSE)
are a family of fatal neurodegenerative diseases affecting several mam-
malian species. TSE were ﬁrst reported in sheep as scrapie but, then,
were also observed to occur in other mammals like humans. They are
thought to be caused by aggregation andmisfolding of the prion protein
(PrP). According to the “protein-only” hypothesis [1–3], PrP undergoes
α-to-β transition from its native state (PrPC) to a misfolded conforma-
tion (PrPSc), which is believed to act as a template to “infect” and mis-
fold other PrP molecules. The misfolded PrPSc is characterized by
some peculiar biochemical properties, such as the resistance to protein-
ase K (PK) and the ability to form insoluble aggregates observed as ce-
rebral accumulations in different TSE [4]. The identiﬁcation of the
structural region(s) of PrP involved in the oligomerization process is
still an open issue, and would help in explaining the molecular mecha-
nism of the aggregation process. Different protein domains have been
proposed as ﬁbrillogenic seed. PrPC consists of a rather ﬂexible N-
terminal arm (residues 23–124) and a well folded C-terminal domain
(residues 125–234) made up of three helixes (H1, H2 and H3) and ainase; PK, proteinase K; Hy,
, monodansylcadaverine; ThT,
ce, Via Università, 100, 80055
rro).
rights reserved.short-stranded β-sheet (formed by S1 and S2) [5]. H2 and H3 give rise
to a hairpin stabilized by a disulﬁde bridge and recent studies [6,7]
have demonstrated that this region is strictly involved in the oligomer-
ization process that preludes amyloid formation. Several experimental
approaches, including site directed mutagenesis, have been utilized so
far to impose a speciﬁc structure to the PrP [8], in order to collect in-
sights for decoding the molecular bases of the aggregation process. In
the present paper, we successfully explored the possibility to use the
enzyme transglutaminase (TG) to covalently modify a recombinant
ovine PrP and, consequently, we studied the effects of such structural
modiﬁcation on some biological properties of the protein.
TG (protein-glutamine γ-glutamyl transferase, E.C. 2.3.2.13) catalyzes
the formation of intra- or inter-molecular ε(γ-glutamyl)lysine crosslinks
into proteins via an acyl-transfer reaction, the γ-carboxamide group of
endoprotein glutamine serving as acyl donor and the ε-amino group of
endoprotein lysine serving as acyl acceptor [9]. The enzyme is also able
to recognize polyamines as acyl acceptors thus producing mono- and
bis-(glutaminyl) polyamine derivatives [10]. TG is a ubiquitous enzyme
and several isoforms are distributed in animals, plants and microorgan-
isms [11]. There exist many different TG molecular forms in mammals,
some of which are endowed with clariﬁed biological functions [12]. For
example activated Factor XIII crosslinks ﬁbrin at the last step of blood co-
agulation, while TG 1 is essential for the correct formation of the epider-
mis [13]. On the contrary, the so-called “tissue enzyme”, the most widely
distributed TG isoform, has a still unexplained function, even though a
possible involvement of this enzymehas beenproposed in several biolog-
ical phenomena like apoptosis [11] and in some neurodegenerative
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fact, it has been established that the “tissue TG” activity increases in the
mentioned pathological states and is able to crosslink β-amyloid and
tau proteins, α-synuclein and neuroﬁlament proteins [15]. Tissue TG
has also been successfully used as biotechnological tool to modify the
biological activities of various peptides and proteins by covalently
linking polyamines to their reactive endo-glutamine residues [16–23].
More recently, we have largely utilized also a microbial isoform of the
enzyme – possessing a wider substrate speciﬁcity, calcium indepen-
dence and high thermostability – to modify protein structure and func-
tion [24–37]. In thiswork, themicrobial enzymewas used tomodify the
structure of a recombinant ovine form of PrP to establish a relationship
between PrP structure and amyloid ﬁbril formation.
2. Materials and methods
2.1. Materials
The ovine PrP used in this study is the sheep ARQ genetic variant
with a MM of 23 kDa produced in E. coli as recombinant form. The
obtained protein corresponds to the fragment 25–234 of the full-
length sequence (UniProtKB P23907) lacking the N-terminal signal
and the C-terminal peptide, with an additional serine residue at its
N-terminus [38]. The recombinant PrP, supplied as a lyophilized pow-
der (a gift from Prof. Liliana Gianfreda [39]), was dissolved in 50 mM
sodium acetate buffer pH 5.5. Microbial TG, Activa WM (speciﬁc
activity=92 U/g; 1 U is deﬁned as the amount of enzyme that cata-
lyzes the formation of 1 μmol of hydroxamate from hydroxylamine
and CBZ-L-glutaminylglycine within 1 min at pH 6.0 at 37 °C) was
obtained from Ajinomoto Co (Hamburg, Germany). The enzyme was
prepared by dissolving the commercial preparation (containing 1%
TG and 99% maltodextrins) in distilled water. Proteinase K (PK)
(from Tritirachium album, lyophilized powder, 14.3 units/mg of pro-
tein), hydroxylamine (Hy), putrescine (Pt), spermidine (Spd), mono-
dansylcadaverine (MDC), thioﬂavin T (ThT), dithiothreitol (DTT),
iodoacetic acid (IAA), α-cyano-4-hydroxycinnamic acid and sinapinic
acid were obtained from Sigma-Aldrich (St. Louis, Mo, USA). Sequenc-
ing grade modiﬁed trypsin (porcine) was from Promega (Madison,
WI, USA). Acrylamide/bis solution, Coomassie Brilliant Blue R-250
and protein molecular weight markers for SDS-PAGE analyses were
from Bio-Rad (Hercules, CA, USA). All other reagents and solvents
were of the highest purity available from Carlo Erba (Milan, Italy).
2.2. TG-modiﬁcation assays
TG-modiﬁcation assays of PrP were carried out at 37 °C for 2 h in
80 mM Tris buffer, pH 7.5 (ﬁnal volume of 50 μL) containing 50 μg
of PrP (43.5 μM) and increasing amounts of microbial TG (0.1, 0.25,
0.5, 2.5, 4.6, 9.2 e 18.4 mU). Control tests were set up without the en-
zyme. Under the same reaction conditions we performed the assays
in the presence of different amounts (0.1, 0.5, 1, 2.5 and 5 mM) of
Hy, Pt and Spd or in the presence of MDC at the ﬁnal concentration
of 5 mM. At the end of the incubation, the reactions were stopped
by heating samples at 100 °C for 5 min and an aliquot of each assay
mixture was subjected to 15% SDS-PAGE analysis. Further details are
given in the ﬁgure legends.
2.3. SDS-PAGE
SDS-PAGE analyses were carried out under reducing conditions on
slab gels (5% stacking and 15% separating gels) as described by
Laemmli [40]. Electrophoresis was performed at constant voltage
(80 V), and the proteins were stained with Coomassie Brilliant Blue
R-250. Precision Protein Standards (Bio‐Rad) were used as molecular
weight markers.2.4. In situ trypsin hydrolysis of protein bands
Coomassie stained protein bands were manually excised from
SDS-gels and subjected to the following treatments as described by
Mamone et al. [41]:
- destaining: gel slices were destained for three times with 50% aceto-
nitrile (ACN) in 25 mM ammonium bicarbonate (500 μL), and then
dehydrated in ACN and vacuum-dried in a Speed-Vac centrifuge.
- cysteine reduction and alkylation: dried slices were rehydrated in
200 μL of 25 mM ammonium bicarbonate containing 10 mM DTT
and incubated at 56 °C for 90 min. At the end of incubation the
DTT solution was removed and substituted with a solution con-
taining 55 mM IAA in 25 mM ammonium bicarbonate (200 μL) and
the samples were incubated 45 min at room temperature. Then,
again the IAA solution was removed and, after several washes with
25 mM ammonium bicarbonate, the gel slices were dehydrated in
ACN and vacuum-dried in a Speed-Vac centrifuge.
- in gel trypsin hydrolysis: each gel piece was then swollen up again in
9 μL of 25 mM ammonium bicarbonate containing 12 ng/μL of tryp-
sin and left on ice for 30 min. The excess of enzymatic solution was
removed and 50 μL of 25 mM ammonium bicarbonate was added
to the gel pieces. Digestion proceeded overnight at 37 °C. Peptides
were extracted with 50% ACN, 5% formic acid by three extraction
steps, with intermittent sonication. The peptide extracts from each
band were then combined, dried in Speed-Vac and resuspended in
50% ACN, 5% formic acid for the following analyses.
2.5. Matrix-assisted laser desorption ionization time of ﬂight mass
spectrometry (MALDI-TOF-MS) analysis
MALDI-TOF-MS analysis was carried out on unmodiﬁed and TG-
modiﬁed PrP as well as on their derived tryptic peptides. For the full
proteins the sinapinic acid (3,5-dimetoxy-4-hydroxy-cinnamic acid)
was used as matrix, while the α-cyano-4-hydroxy-cinnamic acid was
used for tryptic peptides. In all experiments, 1 μL of sample was added
to 1 μL of selected matrix (10 mg/mL in 50% ACN-0.1% triﬂuoracetic
acid, v/v) and then loaded onto the MALDI plate and dried under ambi-
ent conditions.
All mass spectra were generated on a MALDI-TOF mass spectrometer
Voyager DE-Pro (Per-Septive Biosystem, Framingham, MA 01701, USA)
operating either in linear or in reﬂector mode with delay extraction tech-
nology, calibrated using an external standard SIGMA. The laser intensity
(N2, 337 nm, 3 ns pulse width) was set at 20 kV for peptides or 25 kV
for intact proteins and pulsed every 3 ns. Mass spectra were acquired
from each sample by accumulating 250 laser shots. External mass cali-
bration was performed with the signal of a standard peptide or protein
mixture, achieving an accuracy in the measurement of peptide mass
better than 60 ppm (reﬂector mode) and 100 ppm (linear mode). Sig-
nals recorded in the MALDI-TOF spectra were associated with the
corresponding tryptic peptides on the basis of themolecularweight cal-
culated from the reported sequence (UniProtKB P23907) and taking
into account the known enzyme speciﬁcity by using a suitable comput-
er program (GPMAW 5.1, Lighthouse data, Odense, Denmark).
2.6. Amyloid ﬁbril formation and ThT ﬂuorescence measurements
Amyloid ﬁbril formation was performed in 80 mM Tris buffer, pH
7.5, with 43.5 μM PrP in the presence of microbial TG (0.092 mU/μg
of PrP). Control tests were set up without enzyme. For the ﬁrst set
of experiments the samples were incubated for 2 h at 37 °C and, after-
wards, warmed up to 85 °C and let cool down at room temperature. In
further experiments the above described assay mixtures were ﬁrst
treated at 45 °C for 1 h and then incubated at 37 °C. Protein aggrega-
tion was monitored taking aliquots of proteins (50 μL) at different
times. In both cases, the presence of amyloid ﬁbrils was detected by
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to each assay mixture and the ﬁnal volume was adjusted to 120 μL
with 80 mM Tris buffer, pH 7.5. The protein/ThT molar ratio was
1:4. ThT ﬂuorescence was detected by a Perkin–Elmer Life Sciences
LS 55 spectroﬂuorimeter using a 2 mm×10 mm optical path length
rectangular cuvette (Hellma, Germany). Fluorescence emission spec-
tra were recorded from 460 to 600 nm (emission slit was 10 nm)
after excitation at 435±5 nm with each spectrum being the average
of six scans. The temperature was kept constant at 25 °C using an ex-
ternal bath circulator. The ﬂuorescence intensity at 482 nm was
corrected by subtracting the emission intensity recorded before the
addition of protein to ThT solutions.
2.7. PK digestion assay
PK digestionwas performed in 80 mMTris buffer, pH 7.5, at 37 °C in
the presence of 2.8 μg/mL (97 nM) PK and 0.93 μg/μL (40 μM)PrP or TG-
modiﬁed PrP in a ﬁnal volume of 53 μL. Proteolysis was monitored by
analyzing (15% SDS-PAGE) aliquots of the reaction mixtures (10 μL)
withdrawn at different incubation times (5, 15, 30 and 60 min). The re-
action was immediately stopped by adding 2.5 μL of Laemmli Buffer 5×
[40] followed by instant boiling.
3. Results
3.1. Recombinant ovine PrP acts as TG substrate
In the attempt of verifying whether the ovine PrP, variant ARQ, is
able to act as TG substrate, in vitro crosslinking assays were performed.
Hence, PrP was treated with increasing amounts of the enzyme and, at
the end of incubation, an aliquot of the reaction mixture was analyzed
by SDS-PAGE. The extent of crosslinking was evaluated mostly observ-
ing the decrease of the intensity of the protein band of about 23 kDa.
As shown in Fig. 1, a clear attenuation of the PrP bands occurs when
TGwas added to the reaction mixture. At the same time, as the amount
of the enzyme increased, a band migrating faster than the untreated
protein appeared on the gel. In the samples containing more than
2.5 mUof TG a unique band, exhibiting the same electrophoretic mobil-
ity of the 20 kDa MWmarker, was observed. These results suggest that
PrP is endowed with both glutamine and lysine reactive residues and
that the 20 kDa band is due to the enzyme-dependent intra-molecular
crosslinking produced inside the protein. To support this hypothesis,
parallel assays were set up in the presence of Hy (Fig. 2-A), since it is
well known that the addition of this amine, acting as exogenous TGFig. 1. Crosslinking of PrP subjected to TG treatment. PrP (50 μg) was incubated at 37 °C
for 2 h (ﬁnal volume 50 μL) in the presence of increasing amounts of TG. Control was
simultaneously run in the absence of the enzyme (lane 1). The reactions were stopped
by heating of the samples at 100 °C for 5 min. Aliquots of the reaction mixture (10 μL)
were then treated with sample buffer and analyzed by 15% SDS-PAGE. Proteins were
visualized by Coomassie staining. PrP and TG-modiﬁed PrP bands are indicated by
dashed and solid arrows, respectively. St, molecular weight standards (Precision Plus
Protein Dual Color Standards, Bio‐Rad).acyl acceptor substrate [10], is able to effectively counteract protein
crosslinking [42]. The presence of glutamine reactive residue(s) in PrP
protein was also evaluated by incorporating MDC, a ﬂuorescent amine
that also acts as acyl acceptor substrate for TG [43]. The incorporation
of MDC was studied using increasing amounts of the enzyme keeping
constant the concentration of the ﬂuorescent marker. As shown in
Fig. 2-B, using 4.6 mU of TG, ﬂuorescent bands of 23 and 20 kDa were
revealed, while a stronger signal at 20 kDa is obtained with the highest
amount of the enzyme. In another set of experiments two additional
polyamines were tested for their ability to act as TG alternative acyl ac-
ceptor substrates. In particular, Pt and Spd were used at different con-
centrations and their behavior was compared with the one exhibited
by Hy. The results, shown in Fig. 3, demonstrate that, while Hy was
able to counteract PrP crosslinking at each concentration used, Pt and
Spd were effective only at the higher concentrations. In fact, the pres-
ence of both 23 and 20 kDa bands was revealed suggesting that the ε-
amino group(s) of speciﬁc lysine residues was (were) more effective
acyl acceptor substrates compared to the amino group of the tested al-
iphatic polyamines.
3.2. Mass spectrometry analysis of TG-modiﬁed recombinant ovine PrP
Once demonstrated that the shift in electrophoretic mobility of
the TG-treated PrP was enzyme dependent, mass spectrometry anal-
ysis was performed to determine the number of intra‐molecular
isopeptide bonds introduced by TG into the PrP molecule. Aliquots
of protein withdrawn from the reaction mixture carried out in the
presence of 4.6 mU of the enzyme, as well as from the control sample,
were analyzed through MALDI-TOF-MS. Comparing the mass signal
proﬁle of PrP with that of TG-modiﬁed PrP it is clear that the mass
peak corresponding to the latter protein (Fig. 4-A, black proﬁle) has
a lower molecular mass with respect to unmodiﬁed PrP (Fig. 4-A,
gray proﬁle). More precisely, the TG-modiﬁed protein showed a mo-
lecular mass decreased of about 52–53 mass units. Since this number
corresponds to a 3 times multiple of 17.03 (molecular mass of NH3),
which is the mass unit reduced value expected for the formation of
a single isopeptide bond, we conclude that TG was able to introduce
3 intra-molecular crosslinks in a single PrP molecule. It is worth not-
ing that the spectrum of the TG-modiﬁed PrP lacked any signals for
single or double crosslinked protein forms, thus suggesting that the
PrP modiﬁcation kinetics by TG has a cooperative behavior in which
the formation of the ﬁrst intra‐molecular isopeptide bond drives the
molecule to an easier production of the following intra-molecular
crosslinks.
To further investigate the PrP structural modiﬁcation catalyzed by
TG, the protein electrophoretic bands corresponding both to
unmodiﬁed and TG-modiﬁed PrP (Fig. 4-B) were subjected to peptide
mass ﬁngerprinting analysis by trypsin digestion and identiﬁcation of
derived fragments by MALDI-TOF-MS combined with computational
analysis. The theoretical and experimental masses of the obtained
peptides are listed in Table 1. Peptides derived from PrP digestion
covered almost the entire sequence of the protein (Fig. 4-C, dashed
underlines), indicating that the majority of the trypsin sites was ex-
posed and easily recognized by the proteolytic enzyme. Conversely,
for the TG-modiﬁed PrP the peptide mapping allowed to cover only
the C-terminal region of the sequence (from 114 to 223, Fig. 4-C,
solid underlines), while no fragments deriving from the extreme C-
terminal region (from amino acid 224 to the end of protein) were
found as well as from the N-terminal region of the protein until lysine
residue in position 113. The absence of protein fragments in the latter
regions could be explained by hypothesizing that the modiﬁcation in-
troduced by TG caused a structural change of the molecule able to
mask the trypsin sites which became no longer accessible for the pro-
teolytic enzyme. This could probably occur because of the formation
of 3 intra-molecular crosslinks involving one of the two glutamines
present at the C-terminal (peptides 224–231) region and two of the
Fig. 2. Effect of hydroxylamine (Hy) and monodansylcadaverine (MDC) on TG-mediated crosslinking of PrP. PrP (50 μg) was incubated at 37 °C for 2 h (ﬁnal volume 50 μL) in the
presence of increasing amounts of the enzyme in the absence or presence of Hy (A) or MDC (B). The reactions were stopped by heating of the samples at 100 °C for 5 min. Aliquots
of the reaction mixture (10 μL) were then treated with sample buffer and analyzed by 15% SDS-PAGE. Proteins were visualized by Coomassie staining (panel A) or ultraviolet illu-
mination (panel B). St, molecular weight standards (Precision Plus Protein Dual Color Standards, Bio‐Rad).
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41–110). On the other hand, the three lysine residues involved in
the three isopeptide bonds produced by TG should be all present in
the N-terminal region (peptides 25–109) which contains six lysine
residues.
3.3. Amyloid ﬁbril formation and aggregation kinetics studies
In order to investigate whether the 3 intra-crosslinks introduced by
TG into recombinant ovine PrP are able to modify its property to form
amyloid ﬁbrils, ThT ﬂuorescence measurements both on refolded
unmodiﬁed and TG-modiﬁed PrP were performed as described by
Rezaei et al. [44]. ThT is a dye able to form a complex with the β-cross
structure and its ﬂuorescence intensity increases proportionally with
the amount of ﬁbrils present when the ThT concentration is held con-
stant [45,46]. To induce thermal denaturation and subsequent refolding
of PrP, the assay mixtures, incubated in the absence and presence of TG,
were subjected to heat treatment up to 85 °C followed by cooling
at room temperature. As shown in Fig. 5-A, both unmodiﬁed and TG-Fig. 3. Effect of polyamines on TG-mediated crosslinking of PrP. PrP (50 μg) was incubated
creasing amounts of Hy, Pt or Spd. Controls were set up in the absence of the enzyme (lan
reactions were stopped by heating of the samples at 100 °C for 5 min. Aliquots of the reac
PAGE. Proteins were visualized by Coomassie staining. St, molecular weight standards (Premodiﬁed refolded PrP were able to bind ThT giving a typical ﬂuores-
cence emission spectrum with a maximum at 482 nm, while the native
forms, used as control, did not show any ﬂuorescence emission in the
analyzed range, being overlapped to ThT based line. This result, while
conﬁrming that the heat treatment leads to amyloid formation, is a
strong evidence that the presence of the 3 intra-molecular crosslinks
does not affect the ability of the TG-modiﬁed PrP in forming amyloid ag-
gregates. Furthermore, we also tested whether the conversion rate of
the recombinant ovine PrP into amyloid ﬁbrils under non denaturing
conditions was inﬂuenced by the modiﬁcation of the protein catalyzed
by the enzyme. Hence, PrPwas incubated alone or in the presence ofmi-
crobial TG in Tris buffer (pH7.5) at 45 °C for 1 h and then placed at 37 °C.
Aliquots of PrP were withdrawn at different times and ThT ﬂuorescence
intensity at 482 was measured (Fig. 5-B). No ﬂuorescence increase was
observed in the ﬁrst 8 days of incubation for both unmodiﬁed and TG-
modiﬁed PrP. Afterwards, ThT stained aggregates started to appear
with a signiﬁcantly different rate, i.e., TG-modiﬁed PrP faster than
unmodiﬁed PrP. Therefore, the increased ﬂuorescence observed in the
presence of TG suggests a higher tendency to form amyloid aggregatesat 37 °C for 2 h (ﬁnal volume 50 μL) in the presence of 4.6 mU of the enzyme and de-
e 1) or in the presence of the enzyme and in the absence of polyamines (lane 2). The
tion mixture (10 μL) were then treated with sample buffer and analyzed by 15% SDS-
cision Plus Protein Dual Color Standards, Bio‐Rad).
Fig. 4. Mass spectrometry characterization of unmodiﬁed and TG-modiﬁed PrP. Panel A — spectra of unmodiﬁed (gray line) and TG-modiﬁed (black line) PrP are presented.
Reported mass signals refer to singly charged molecular ions. Peaks marked with asterisks correspond to artifacts due to the formation of adducts with the matrix. The analyzed
PrP samples were taken from the mixture of the assays carried out in the absence or the presence of TG, respectively. Panel B — electrophoretic proﬁle of the samples (10 μL) an-
alyzed by MALDI-TOF-MS (panel A). The protein bands corresponding to PrP and to TG-modiﬁed PrP (dashed and solid arrows, respectively) were cut from gel and treated with
trypsin for further analyses. Panel C — sequence of recombinant PrP and of the peptides derived from in situ trypsin digestion of unmodiﬁed (dashed underlines) and TG-
modiﬁed (solid underlines) PrP, identiﬁed by MALDI-TOF-MS. The arrows indicate the putative trypsin cleavage sites. Glutamine (Q) and lysine (K) residues are highlighted.
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(Fig. 5-B).
3.4. TG-modiﬁed PrP protease resistance
Further biochemical characterization of TG-modiﬁed recombinant
ovine PrP, compared to unmodiﬁed PrP, was achieved by testing pro-
tein resistance to PK digestion. Digested samples were analyzed by
15% SDS-PAGE (Fig. 6) and, as expected, the unmodiﬁed PrP resulted
very sensitive to PK treatment, being almost completely degraded
after only 5 min of incubation (Fig. 6, lane 2). On the contrary, the
TG-modiﬁed PrP showed a marked resistance to PK hydrolysis, the
corresponding 20 kDa band remaining almost uncleaved even after
15 min of PK treatment (Fig. 6, lanes 8 and 9).
4. Discussion
In this study we investigated the ability of recombinant ovine PrP
to act as substrate of a TG microbial isoform. The PrP used in our ex-
periments possesses 17 glutamine and 11 lysine residues differentlydistributed in the primary structure of the protein. We have demon-
strated that some of these residues are able to act either as acyl
donor or acyl acceptor substrates for the enzyme giving rise to a
PrP modiﬁed form with a faster electrophoretic mobility compared
to the unmodiﬁed PrP. Similar results were previously obtained by
Konno et al. [47], by using tissue TG, in the attempt of ﬁnding a rela-
tion between intra-crosslinking and amyloid formation process of
the prion-like Sup35 protein isolated from yeast and of the human
tau and α-synuclein proteins. They found that all three TG-modiﬁed
proteins showed a higher electrophoretic mobility probably due to a
more compact structure of the proteins after the formation of an intra‐
molecular crosslink assessed by MS experiments. In the present paper
we have demonstrated the presence of three intra-molecular crosslinks
between glutamine and lysine residues occurring in the tested PrP that,
presumably, are very close in the 3D structure of the protein. In fact, the
lowmolecularweightHy is the only amine, among those examined, able
to effectively counteract the ε(γ-glutamyl)lysine crosslink formation of
the PrP. MS experiments indicated that two of the three TG-mediated
intra-molecular isopeptide bonds occur at the N-terminal region, since
no signals were detected after trypsin digestion in the unstructured
Fig. 5. Amyloid ﬁbril formation. Panel A — ﬂuorescence spectra of ThT in the presence of
unmodiﬁed and TG-modiﬁed PrP. The refolded forms of both PrP protein forms were
obtained by denaturation at 85 °C followed by refolding at room temperature (dashed
and dashed-dotted lines). The unheated unmodiﬁed and TG-modiﬁed PrP were used as
control (dotted and solid lines). Emission spectra were recorded at 25 °C. Excitation
was performed at 435 nm. Protein concentration was 18 μM, and the ThT/protein
molar ration was 4:1. Panel B — time course of ThT ﬂuorescence obtained in native-like
conditions. PrP (43.5 μM) was incubated either in the absence (empty bars) or presence
(striped bars) of TG (0.092 mU/μg of PrP) at 45 °C for 1 h and then placed at 37 °C. The
ﬁbril formation was evaluated at different incubation times by recording ThT ﬂuores-
cence spectra between 460 and 600 nm, with excitation at 435 nm. The protein con-
centration was 18 μM, and the ThT/protein molar ratio was 4:1. The ThT ﬂuorescence
at 482 nm was plotted at each incubation time.
Table 1
MALDI-TOF MS assignments of peptide fragments obtained following in situ trypsin di-
gestion of both unmodiﬁed and TG-modiﬁed PrP.
Identiﬁcation m/z (Da)
Theoretical Experimental
PrP TG-modiﬁed PrP
155–159 711.80 – 712.80
189–197 1016.10 – 1017.13
224–231 1044.10 1045.17 –
41–51 1090.14 1090.16 –
198–207 1153.12 1154.22 1154.22
152–159 1194.34 1195.08 –
27–40 1426.57 1426.98 –
212–223 1554.82 1555.82 1555.79
25–40 1769.99a 1770.65 –
189–207 2151.32 2152.65 –
189–211 2680.98 2682.05 –
160–188 3575.81 3576.77 3576.93
114–151 3789.00 3790.54 3790.28
110–151 4263.86 4264.56 –
160–197 4574.03 4575.63 –
52–109 5787.14 5788.98 –
a The theoretical mass of this peptide was calculated taking into account the pres-
ence of an additional serine residue at the N-terminal end, as a result of the PrP
cDNA subcloning for the production of the recombinant protein used in this work [38].
Fig. 6. Susceptibility of unmodiﬁed and TG-modiﬁed PrP to PK digestion. PrP (42.8 μM)
was incubated at 37 °C in 80 mM Tris buffer, pH 7.5, in the absence (A) or presence (B)
of 4.6 mU of TG in a ﬁnal volume of 60 μL. After 2 h of incubation, a sample of 10 μL of
each reaction mixture was taken and then 3 μL of PK solution (50 μg/mL) was added to
the remaining reaction mixtures. The incubation was then prolonged for 1 h and other
aliquots (10 μL) of digestion mixtures were taken at 5, 15, 30 and 60 min and analyzed
by 15% SDS-PAGE. Further details are given under Materials and methods section. PrP
and TG-modiﬁed PrP intact bands are indicated by dashed and solid arrows, respective-
ly. St, molecular weight standards (Precision Plus Protein All Blue Standards, Bio‐Rad).
1514 A. Sorrentino et al. / Biochimica et Biophysica Acta 1822 (2012) 1509–1515domain from theN-terminal end and lysine 113. It isworthy to note that
this region is very close to the “seeding part” of PrP where two β-
strands represent the protein domain fromwhich starts the conversion
between the non infective conformation of the protein and the patho-
logical one, which is an amyloid. Rezaei and colleagues [8] introduced
by site directed mutagenesis 2 cysteine residues (at position 160 and
209) to give rise to a disulphide bond stabilizing the 3D structure of
PrP. They have, in this way, demonstrated that the disulﬁde bond led
to the formation of a more compact structure able to prevent oligomer-
ization and, as a consequence, amyloid aggregation.
In our study we have observed that the presence of TG-mediated
intra-molecular crosslinks at the N-terminal end of PrP determines a
higher proneness of the protein in forming amyloid aggregates in com-
parison with the unmodiﬁed PrP. This feature has been also conﬁrmed
by PK digestion experiments. In fact, one of the typical characteristics
of the prion proteins is the different resistance to PK treatment of
their different conformational forms. Several authors reported that the
normal non pathogenic cellular form (PrPC), fully folded to α-helix
structure, is easily proteolyzed by PK, while the so-called infectious
form (PrPSc), the secondary structure of which is rich in β-strands, is
partially resistant to PK treatment [48–50]. Therefore, our results sug-
gest that the TG-mediated structural modiﬁcations of PrP determine
signiﬁcant changes of the protein, which are responsible for its PK resis-
tance. In fact, taken together, the present data support the conclusion
that TG gives rise to amodiﬁed PrP formpossessing a structure that pro-
vokes more easily the spatial separation between the H2 and H3
domains from the rest of the molecule, triggering, in this way, the olig-
omerization process. Our hypothesis is in agreement with Rezaei and
colleagues' studies which have recently established a role for the H2
and H3 helixes as a region of the protein essential to determine oligo-
merization and amyloid formation [6,7]. The present data indicate,
thus, that the use of TG could be particularly suitable for exploring the
structural basis of the PrPC–PrPSc conversion and, as a consequence,
for clarifying the molecular mechanism of the prion dependent neuro-
degenerative diseases.Acknowledgements
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